Article

Retina specialists still searching for more effective AMD therapies

The excitement in retina during the past year has been about the promise of the development of more effective treatments for age-related macular degeneration (AMD). However, the excitement has been mixed with a measure of disappointment surrounding the therapies in the pipeline but tempered by the possibility of combination therapies that warrant exploration and tweaking.

Among other developments, various technologies and procedures have been refined, making diagnosis of retinal diseases and surgery easier. These include optical coherence tomography (OCT), the latest generation of which produces impressive details of the retinal microstructures on the scans, and fiberoptic endoscopy, which may become valuable for visualization in difficult vitrectomy cases. In addition, development of sustained-release delivery systems may facilitate easier treatment of retinal diseases.

AMD The evaluations of three major therapies that are in trials represent a purely pharmacologic approach to the treatment of wet AMD.

Mark Hughes, MD, echoed that sentiment and heralded combination therapy as the wave of the future.

"We were expecting something better from pegaptanib sodium. However, it is a big step forward. This pharmacologic therapy, in addition to a photoenhancing approach, means that we are developing a more sophisticated understanding of treatment of the AMD disease process," said Dr. Hughes, who is a member of Ophthalmic Consultants of Boston, and senior surgeon, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
© 2025 MJH Life Sciences

All rights reserved.